BeiGene to Present at Upcoming Investor Conferences
read more...
Sep 21, 2018
BeiGene Announces Preliminary Results from the Phase 1 Clinical Trial of Zanubrutinib in Chinese Patients with B-Cell Lymphoma at Annual Meeting of the Chinese Society of Clinical Oncology
read more...
Sep 20, 2018
BeiGene Presents Results on Anti-PD-1 Antibody Tislelizumab in Chinese Patients with Lung Cancers at the Annual Meeting of the Chinese Society of Clinical Oncology
read more...
Sep 20, 2018
BeiGene Presents Preliminary Results on Anti-PD-1 Antibody Tislelizumab in Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors at Annual Meeting of the Chinese Society of Clinical Oncology
read more...
Sep 16, 2018
BeiGene Announces Oral Data Presentations at Annual Meeting of the Chinese Society of Clinical Oncology
read more...
Sep 07, 2018
BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors
read more...
Sep 05, 2018
BeiGene to Present Data on Anti-PD-1 Antibody Tislelizumab at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto
read more...
BeiGene to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
read more...
Aug 31, 2018
BeiGene Announces Acceptance of New Drug Application for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma in China
read more...
Aug 26, 2018
BeiGene Announces Acceptance of its First New Drug Application for Zanubrutinib in Relapsed/Refractory Mantle Cell Lymphoma by China Drug Administration
read more...
Aug 09, 2018
BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China
read more...
Aug 09, 2018
BeiGene Reports Second Quarter 2018 Financial Results
read more...
Aug 08, 2018
BeiGene Announces Closing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering
read more...
Aug 02, 2018
BeiGene Announces Pricing of Its HK$7.08 billion (US$903 million) Hong Kong Initial Public Offering and Global Offering
read more...
Jul 27, 2018
BeiGene Announces Proposed Hong Kong Initial Public Offering and Global Offering
read more...
Jul 24, 2018
BeiGene Initiates Phase 3 Pivotal Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer in China
read more...
Jul 24, 2018
BeiGene Initiates Global Phase 3 Trial of PARP Inhibitor Pamiparib in Patients with Advanced Gastric Cancer
read more...
Jul 22, 2018
BeiGene Announces Preliminary Topline Results of Pivotal Trial in China for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma
read more...
Jul 22, 2018
BeiGene Announces Plan to Pursue Accelerated Approval in the U.S. of BTK Inhibitor Zanubrutinib in Waldenström Macroglobulinemia (WM)
read more...
